FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF CHANGES | IN BENEFICIAL | OWNERSHIP |
|-----------|-------------------|---------------|-----------|

| l | OMB APPRO | VAL |
|---|-------------------------|-----------|
| | OMB Number: | 3235-0287 |
| l | Estimated average burde | en |
| l | hours per response: | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* | | | | | 2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES INC NBIX | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | |
|--|--------|---------|------------------------|-----|---|---|-------|---|--|---------------------------------------|--------|--------------|---|---|----------------------|---|---|---|--|
| GORMAN KEVIN CHARLES | | | | | | | | | | | | | | X | Direc | ctor | 10% Owner | | wner |
| (Last) (First) (Middle) | | | | | <u> </u> | - | | | | | | | X | Office belov | er (give title v) | | Other (below) | specify | |
| 12780 EL CAMINO REAL | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 01/10/2017 | | | | | | | Chief Executive Officer | | | | | | |
| (Street) | | | | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | |
| SAN DIE | CGO CA | A 9 | 2130 | | | | | | | | | | | X | Form | n filed by One | e Reporti | ng Pers | on |
| (City) | (St | ate) (2 | Zip) | | | | | | | | | | | | Form Pers | rm filed by More than One Reporting rson | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day | | | | | Execution Date, | | Date, | 3. Transaction Code (Instr. 8) 4. Securities Acquired (AD Disposed Of (D) (Instr. 3) | | | | | Securi Benefi Owner | Securities Beneficially | | ership Direct Idirect I. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | | | | | | v | Amount | (A) o (D) | Price | • | Transa | ction(s) 3 and 4) | | (iiisti. 4 | (111511. 4) |
| Common Stock 01/10/20 | | | | | 2017 | | | | S ⁽¹⁾ | | 3,750 | D | \$43 | 3.28 ⁽²⁾ | 240,927 | | Г |) | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security Security 3. Transaction Date (Month/Day/Ye) | | | Execution Date, if any | | | ransaction Code (Instr.) | | mber ative rities ired osed | 6. Date Exerc Expiration Da (Month/Day/Y | | te | e Amount of | | 8. Price of Derivative Security (Instr. 5) | | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | Owr Forr Dire or Ir (I) (I | Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | Code | | v | (A) | (D) | Date Exercis | able | Expiration Date | Title | Amoun or Number of Shares | | | | | | | | | |

Explanation of Responses:

1. Sale of 3,750 shares of common stock issued upon vesting of 7,500 restricted stock units on January 10, 2017 to cover payroll and withholding taxes, with the balance of the shares (3,750) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from \$42.50 to \$45.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Remarks:

/s/Darin Lippoldt, Attorney-In-Fact 01/12/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.